The company has announced that MSD has already submitted a request for the approval of a medication that combines a selective DPP-4 inhibitor and a selective SGLT2 inhibitor.
Astellas Pharma has joined MSD in the treatment of diabetes, and has announced that this pharmacist has already submitted a request for the approval of a medication that combines a selective DPP-4 inhibitor and a selective SGLT2 inhibitor.
Both pharmaceuticals hope to contribute to a greater extent to the treatment of the disease by controlling blood sugar levels with monotherapy.
The drug, called MSD Januvia Tablet is intended to selectively inhibit DPP-4 and increase active incredine levels.For its part, the Astellas inhibitor, Siglat Tablet, selectively inhibits SGLT2 and blocks renal glucose reuptake.
In this sense, both companies expect the combination of their two compounds, with different mechanisms of action for the treatment of type 22 diabetes, reduce the number of medications that these patients require and improve their adhesion.
In this way, both Astellas Pharma and MSD hope to contribute to a greater extent to the treatment of type II diabetes controlling blood sugar levels with monotherapy.
